

## MOLECULAR MODELING TO PREDICT THE LIGAND BINDING KEY EVENT

Sara GIANI TAGLIABUE s.gianitagliabue@campus.unimib.it

University of Milano-Bicocca, Department of Earth and Environmental Sciences, Milan, Italy

Toxic effects of a molecule can be explained by the Adverse Outcome Pathway model (AOP); the molecular initiating event (MIE) can be the interaction of the molecule with a biological target, a protein for example. After the initial interaction many Key Events (KE) can link the MIE to the Adverse Outcome (AO)<sup>1</sup>. It is useful to describe also the **Key Event Relationship** to assess the causal nature between two measurable biological events<sup>2</sup>. Our focus of study is the Aryl hydrocarbon Receptor (**AhR**), a PAS-containing ligand-dependent transcription factor that responds to exogenous and endogenous chemicals with the induction of gene expression and production of diverse biological and toxic effects<sup>3</sup>. Our in-depth study is on the MIE, the ligand binding.

MIE

KE1

KE2

KE

Adverse Outcome tissue- organ- species- specific

ligand bindng

nuclear translocation AhR:ARNT dimer formation

AhR:ARNT DNA binding


KE3

gene expression (cyp1a1)

KE4

unknown mechanisms death, wasting syndrom, oxidative stress, immuno&development toxicity, liver tumor, etc.

cellular, organ, individual



The mechanism is initiated by ligand binding to the cytosolic AhR, then it translocates into the nucleus where it heterodimerizes with its homologous protein ARNT. The dimer binds the xenobiotic-responsive element (XRE) and finally activates the transcription of some target genes (ex. cyp1a1)<sup>4</sup>.

The analysis of specific binding interactions allowed us to identify a subregion of the cavity typical for each group of ligands.

For example TCDD reaches the bottom of the cavity, FICZ establishes an hydrogen-bond at the entrance of the cavity.

Molecular Modeling already allowed a deep comprehension of the key molecular events regulating the mechanism of ligand-dependent and ligand-specific AhR activation<sup>4</sup>.

experimental information is available for this domain.

Anyway it is possible to achieve a structural model by **homology modeling**, *i.e.* a technique that exploits the structural information contained into homologous proteins. The Hypoxia-Inducible Factor 2α (**HIF2α**) dimerizes with the same partner (ARNT) and shows nearly 30% of sequence identity with the mAhR PASB. It was used as template for developing a model with *MODELLER*. A set of **different AhR agonists** (including toxic and endogenous compounds) were docked into the homology models with *Glide XP*. To include protein flexibility we used the **ensemble docking** approach, *i.e.* docking to multiple protein conformations.


The AhR domain responsible for ligand binding is the PASB, unfortunately no

The obtained poses were subjected to **molecular dynamics** simulation to relax the complex. In order to get the most stabilizing contributions we calculated the binding free energy ( $\Delta G$ bind) with the MM-GBSA approach implemented in *Amber* and the  $\Delta G$ bind was decomposed into **per-residue contributions**.

Homology
Modeling
modeller

Ensemble
Docking
glide XP

Molecular
Dynamic
amber



NIH

This research was supported by the National Institute of Environmental Health Sciences (USA) (R01ES007685)

1. Allen TEH, Goodman JM, Gutsell S & Russell PJ "Defining molecular initiating events in the adverse outcome pathway framework for risk assessment" Chem Res Toxicol 27, 2100–12 2014

2. Wittwehr C et al. "How Adverse Outcome Pathways Can Aid the Development and Use of Computational Prediction Models for Regulatory Toxicology" Toxicol Sci 155, 326–336 2016

3. Denison MS, Soshilov AA, He G, DeGroot DE & Zhao B "Exactly the same but different: promiscuity and diversity in the molecular mechanisms of action of the aryl hydrocarbon (dioxin) receptor" Toxicol Sci 124, 1–22 2011

4. Bonati L, Corrada D, Giani Tagliabue S & Motta S "Molecular modeling of the AhR structure and interactions can shed light on ligand-dependent activation and transformation mechanisms" Curr Opin Toxicol 2, 42–49 2017

xic AhR ligand, and FICZ is an endocate and AhR without causing toxicity.

references